Loading...
Immunome Q4 2024 Earnings Report
Immunome reported its full year 2024 financial results and provided a business update.
Key Takeaways
Immunome reported a net loss of $292.963 million for the full year ended December 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $217.3 million as of December 31, 2024, and its cash runway is expected to extend into 2027. Key pipeline updates include topline data for the Phase 3 RINGSIDE study of varegacestat expected in the second half of 2025, the first patient dosed in the Phase 1 clinical trial for IM-1021, and an IND submission for IM-3050.
Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.
First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.
IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy, with a clinical trial anticipated in the second half of 2025.
Projected cash runway extends into 2027, supported by a $172.5 million public offering in January 2025.
Revenue by Segment
Forward Guidance
Immunome anticipates several key clinical milestones in 2025, including topline data for the RINGSIDE trial and initiation of a Phase 1 clinical trial for IM-3050. The company's cash runway is projected to extend into 2027.
Positive Outlook
- Topline data for Phase 3 RINGSIDE study of varegacestat expected in second half of 2025.
- Anticipated initiation of a Phase 1 clinical trial for IM-3050 in the second half of 2025.
- Projected cash runway extends into 2027, providing financial stability.
- Multiple programs now in clinical development, indicating pipeline advancement.
- Three additional novel ADCs (IM-1617, IM-1335, IM-1340) are in IND-enabling manufacturing.
Challenges Ahead
- Clinical trial data may not be predictive of future clinical data.
- Regulatory approvals for programs and product candidates may be delayed or subject to unanticipated conditions.
- Programs and product candidates may fail to achieve their intended endpoints.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...